Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2017 Jan 19;18(1):1–9. doi: 10.3233/CBM-160650

MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1

Yunsheng Guo a,*, Yan Pang a, Xia Gao b, Min Zhao a, Xin Zhang a, Hao Zhang a, Bing Xuan a, Yimin Wang a
PMCID: PMC13020608  PMID: 28035913

Abstract

The mechanisms underlying oxaliplatin (OXA) resistance in colon cancer cells are not fully understood. MicroRNAs (miRNAs) play important roles in tumorigenesis and drug resistance. However, the relationship between miRNA and OXA resistance in colon cancer cells has not been previously explored. In this study, we utilized microRNA microarray analysis and real-time PCR to verify that miR-93, miR-191, miR-137, miR-181 and miR-491-3p were significantly down-regulated and that miR-96, miR-21, miR-22, miR-15b and miR-92 were up-regulated in both HCT-15/OXA and SW480/OXA cell lines. Blocking miR-137 caused a significant inhibition of OXA-induced cytotoxicity, therefore, miR-137 was chosen for further research. An in vitro cell viability assay showed that knockdown of miR-137 in HCT-15 and SW480 cells caused a marked inhibition of OXA-induced cytotoxicity. Moreover, we found that miR-137 was involved in repression of YBX1 expression through targeting its 3'-untranslated region. Furthermore, down-regulation of miR-137 conferred OXA resistance in parental cells, while over-expression of miR-137 sensitized resistant cells to OXA, which was partly rescued by YBX1 siRNA. The results of this study may aid the development of therapeutic strategies to overcome colon cancer cell resistance to OXA.

Keywords: Colon cancer, miR-137, YBX1, drug resistance

References

  • [1]. Liu, S., et al., Incidence and mortality of colorectal cancer in China, 2011. Chin J Cancer Res, 2015. 27(1): p. 22-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2]. Bullock, M.D., et al., Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis, 2013. 4: p. e684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3]. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004. 116(2): p. 281-97. [DOI] [PubMed] [Google Scholar]
  • [4]. Pillai, R.S., MicroRNA function: multiple mechanisms for a tiny RNA? RNA, 2005. 11(12): p. 1753-61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5]. Zamore, P.D. and Haley, B., Ribo-gnome: the big world of small RNAs. Science, 2005. 309(5740): p. 1519-24. [DOI] [PubMed] [Google Scholar]
  • [6]. Luo, C., et al., miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol, 2013. 133(3): p. 768-75. [DOI] [PubMed] [Google Scholar]
  • [7]. Chen, D., et al., MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas. J Oral Maxillofac Res, 2013. 4(1): p. e2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8]. Zhao, Y., et al., MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One, 2012. 7(6): p. e39102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9]. Balaguer, F., et al., Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res, 2010. 70(16): p. 6609-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10]. Liu, T., et al., MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett, 2009. 273(2): p. 233-42. [DOI] [PubMed] [Google Scholar]
  • [11]. Nielsen, B.S., et al., miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer. Front Oncol, 2014. 4: p. 207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12]. Karlson, D., et al., A cold-regulated nucleic acid-binding protein of winter wheat shares a domain with bacterial cold shock proteins. J Biol Chem, 2002. 277(38): p. 35248-56. [DOI] [PubMed] [Google Scholar]
  • [13]. Valadao, A.F., et al., Y-box binding protein from Schistosoma mansoni: interaction with DNA and RNA. Mol Biochem Parasitol, 2002. 125(1-2): p. 47-57. [DOI] [PubMed] [Google Scholar]
  • [14]. Lasham, A., et al., Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene, 2000. 252(1-2): p. 1-13. [DOI] [PubMed] [Google Scholar]
  • [15]. Chatterjee, M., et al., The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood, 2008. 111(7): p. 3714-22. [DOI] [PubMed] [Google Scholar]
  • [16]. Lyabin, D.N., Eliseeva, I.A. and Ovchinnikov, L.P., YB-1 protein: functions and regulation. Wiley Interdiscip Rev RNA, 2014. 5(1): p. 95-110. [DOI] [PubMed] [Google Scholar]
  • [17]. Zhang, X., et al., GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro. Mol Carcinog, 2014. [DOI] [PubMed] [Google Scholar]
  • [18]. Kim, J., et al., Differential association of RANTES-403 and IL-1B-1464 polymorphisms on histological subtypes in male Korean patients with gastric cancer. Tumour Biol, 2014. 35(4): p. 3765-70. [DOI] [PubMed] [Google Scholar]
  • [19]. Szakacs, G., et al., Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 2006. 5(3): p. 219-34. [DOI] [PubMed] [Google Scholar]
  • [20]. Gottesman, M.M., Fojo, T. and Bates, S.E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2002. 2(1): p. 48-58. [DOI] [PubMed] [Google Scholar]
  • [21]. Zhu, W., et al., miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer, 2010. 127(11): p. 2520-9. [DOI] [PubMed] [Google Scholar]
  • [22]. Shang, Y., et al., miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene, 2014. 33(25): p. 3267-76. [DOI] [PubMed] [Google Scholar]
  • [23]. Guo, J., et al., miR-137 suppresses cell growth in ovarian cancer by targeting AEG-1. Biochem Biophys Res Commun, 2013. 441(2): p. 357-63. [DOI] [PubMed] [Google Scholar]
  • [24]. Zhu, X., et al., miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett, 2013. 587(1): p. 73-81. [DOI] [PubMed] [Google Scholar]
  • [25]. Yan, X., et al., High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer. Int J Clin Exp Pathol, 2014. 7(12): p. 8715-23. [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES